High prevalence of BRAF mutations in thyroid cancer: genetic evidence for constitutive activation of the RET/PTC-RAS-BRAF signaling pathway in papillary thyroid carcinoma.
about
Main roads to melanomaPrognostic Role of PIK3CA Mutation in Colorectal Cancer: Cohort Study and Literature ReviewThe RET/PTC-RAS-BRAF linear signaling cascade mediates the motile and mitogenic phenotype of thyroid cancer cellsThe role of microRNA genes in papillary thyroid carcinomaSelumetinib-enhanced radioiodine uptake in advanced thyroid cancerEffects of let-7 microRNA on Cell Growth and Differentiation of Papillary Thyroid CancerTargeting BRAF in thyroid cancerDifferential regulation of B-raf isoforms by phosphorylation and autoinhibitory mechanismsConstitutive activation of the Ras-Raf signaling pathway in metastatic melanoma is associated with poor prognosisPolymorphisms of the BRAF gene predispose males to malignant melanomaPreponderance of the oncogenic V599E and V599K mutations in B-raf kinase domain is enhanced in melanoma cutaneous/subcutaneous metastasesSpotlight on lenvatinib in the treatment of thyroid cancer: patient selection and perspectivesSelective use of sorafenib in the treatment of thyroid cancerRenal effects of BRAF inhibitors: a systematic review by the Cancer and the Kidney International NetworkGenetic Testing in Differentiated Thyroid Carcinoma: Indications and Clinical ImplicationsSomatic DNA mutation analysis in targeted therapy of solid tumoursMEK and PI3K inhibition in solid tumors: rationale and evidence to dateSorafenib in metastatic thyroid cancer: a systematic reviewTreatment strategies for radioactive iodine-refractory differentiated thyroid cancerOncogenic AKAP9-BRAF fusion is a novel mechanism of MAPK pathway activation in thyroid cancer.Dissecting therapeutic resistance to RAF inhibition in melanoma by tumor genomic profiling.Vemurafenib in Multiple Nonmelanoma Cancers with BRAF V600 Mutations.Inhibition of Mutated, Activated BRAF in Metastatic MelanomaTargeted Therapies in Non-Small Cell Lung Cancer-Beyond EGFR and ALKAutophagy in thyroid cancer: present knowledge and future perspectivesIntegrated genomic characterization of papillary thyroid carcinomaB-Raf acts via the ROCKII/LIMK/cofilin pathway to maintain actin stress fibers in fibroblastsLoss of Rap1GAP in papillary thyroid cancerFra-1 promotes growth and survival in RAS-transformed thyroid cells by controlling cyclin A transcriptionOncogenic activation of MAP kinase by BRAF pseudogene in thyroid tumors2015 American Thyroid Association Management Guidelines for Adult Patients with Thyroid Nodules and Differentiated Thyroid Cancer: The American Thyroid Association Guidelines Task Force on Thyroid Nodules and Differentiated Thyroid CancerMolecular genesis of non-muscle-invasive urothelial carcinoma (NMIUC)B-RAF regulation of Rnd3 participates in actin cytoskeletal and focal adhesion organizationCopy number amplification of the PIK3CA gene is associated with poor prognosis in non-lymph node metastatic head and neck squamous cell carcinoma.Significance of the BRAF mRNA Expression Level in Papillary Thyroid Carcinoma: An Analysis of The Cancer Genome Atlas Data.Quantitative and qualitative differences in protein expression between papillary thyroid carcinoma and normal thyroid tissue.Gene expression profiling of papillary thyroid carcinoma identifies transcripts correlated with BRAF mutational status and lymph node metastasis.Down-regulation of NR4A1 in follicular thyroid carcinomas is restored following lithium treatment.Molecular pathways: BRAF induces bioenergetic adaptation by attenuating oxidative phosphorylation.The role of podoplanin in the biology of differentiated thyroid cancers.
P2860
Q21245465-8FFF4A01-D816-4F12-B20A-AB2039CC665BQ24289005-E383DD44-4620-41D6-B224-2CCA72FCBBD6Q24519206-DA512EF7-FBEE-4577-890D-99CC112DC980Q24535848-BBF9C1B6-6E19-4A8A-9088-C1D0838C12E1Q24596266-B2072C5E-3557-4AEA-959A-4521AF2A7DBAQ24652758-B57410B4-E085-4BE6-91D0-CF3C4716C877Q24653496-F3EF9161-6D24-4FA0-830C-54A96CCB3885Q24674150-E91D9632-2187-4EBB-995D-4ECE0B778AB3Q24791830-9297FF46-63F5-40B2-9436-8C830380D278Q24806439-9FEB071D-6800-43AE-92EF-D7CD58BA4459Q24814098-55316D67-A412-4D09-9796-F3F35BCAFCAAQ26751274-662341E9-AD0E-46AA-A2D5-511A3B5500A3Q26752891-C42EE4B8-C84C-4D0A-A1CD-A6C13D63389CQ26764883-0A21EB2A-59CB-40EE-A74C-AC2E54FC597CQ26765085-BE9695BC-E866-4BA5-A222-EDCABE4175DEQ26770324-FE9AC775-C82D-44A6-A549-941AE2434376Q26775573-E41D45EB-C036-4EA6-8EE1-4C3011C8C82BQ26828884-E67FA111-4A62-4DDA-B0CB-347DA7E9505AQ26862841-06299600-C4C6-4163-8307-3A64542400A3Q27824825-11D0D90B-E789-4772-9BFE-C8B03195C8C8Q27851628-7C7AF385-D518-4E99-8DEA-44B5C9852160Q27853199-4AD4E616-9291-4F3B-8B09-0864C4861527Q27860458-62B43A41-80F6-4448-B991-447091A6ADADQ28083446-960AFD04-3108-402E-99B8-02BD3AD74289Q28086785-25D2159B-692A-433F-B9DD-DDCBF5AD353CQ28251986-462EEA35-6318-4B7A-B4BE-913414DC569AQ28508452-316A16AD-01E7-4C8A-A434-5FC3F3A9B34DQ28569254-8EC3463E-CDE8-405E-9B37-1D24FE649E27Q28584124-332A3C1A-9FAB-446F-B2BA-6EC258ABC74CQ28756117-6D585E9C-76E0-4B0C-8EE2-D4B53BC24FCFQ30367068-E442D182-175E-435C-8A11-7DCB5B487B69Q30433431-6629C55A-8877-4D90-8E24-778AD0825EEBQ30443185-6D92A5C8-94E4-4C04-9B6D-77260987CFCCQ31096247-C2227B85-F09C-4EC5-BD75-ACBCB0228BFAQ31114420-2A33EB32-69C2-4A25-BF52-EF2CD5F0B018Q33247421-C199A4B8-7161-482C-8CC5-EC54BD8C728BQ33357290-9C9A70F3-CFAE-410A-BC31-11C908BB4BECQ33363441-3B2A82BB-A86D-435A-9442-77B818D7157EQ33560698-4690BB8F-859F-431D-B338-FA443C48F0CBQ33568168-3B5C3B60-D149-4F56-9529-A1393AFAB46C
P2860
High prevalence of BRAF mutations in thyroid cancer: genetic evidence for constitutive activation of the RET/PTC-RAS-BRAF signaling pathway in papillary thyroid carcinoma.
description
2003 nî lūn-bûn
@nan
2003年の論文
@ja
2003年学术文章
@wuu
2003年学术文章
@zh
2003年学术文章
@zh-cn
2003年学术文章
@zh-hans
2003年学术文章
@zh-my
2003年学术文章
@zh-sg
2003年學術文章
@yue
2003年學術文章
@zh-hant
name
High prevalence of BRAF mutati ...... n papillary thyroid carcinoma.
@en
High prevalence of BRAF mutati ...... n papillary thyroid carcinoma.
@nl
type
label
High prevalence of BRAF mutati ...... n papillary thyroid carcinoma.
@en
High prevalence of BRAF mutati ...... n papillary thyroid carcinoma.
@nl
prefLabel
High prevalence of BRAF mutati ...... n papillary thyroid carcinoma.
@en
High prevalence of BRAF mutati ...... n papillary thyroid carcinoma.
@nl
P2093
P1433
P1476
High prevalence of BRAF mutati ...... n papillary thyroid carcinoma.
@en
P2093
Edna T Kimura
James A Fagin
Jeffrey A Knauf
Marina N Nikiforova
Yuri E Nikiforov
Zhaowen Zhu
P304
P407
P577
2003-04-01T00:00:00Z